A clinical-stage biotechnology company commercializing a novel vaccination platform announced a potential solution for millions afraid of needles.
This vaccine innovation is essential as researchers estimate that fear of needles affects up to 25% of adults and may lead to many people skipping standard vaccinations.
Vaxxas confirmed today it initiated a Phase I clinical trial with the first needle-free inactivated seasonal influenza vaccine quadrivalent (IIV4) candidate delivered using the Company's proprietary high-density microarray patch (HD-MAP) technology.
Fear of Needles Resolved with Pain-less Microarray Patch
Fear of Needles Resolved with Pain-less Microarray Patch
A clinical-stage biotechnology company commercializing a novel vaccination platform announced a potential solution for millions afraid of needles.
This vaccine innovation is essential as researchers estimate that fear of needles affects up to 25% of adults and may lead to many people skipping standard vaccinations.
Vaxxas confirmed today it initiated a Phase I clinical trial with the first needle-free inactivated seasonal influenza vaccine quadrivalent (IIV4) candidate delivered using the Company's proprietary high-density microarray patch (HD-MAP) technology.
Pre-Infection Healthy Lifestyle Tied to Lower Risk for Long COVID
Healthy body mass index and adequate nightly sleep showed highest preventive benefit
Recommended 2023 Adult Immunization Schedule Published
Changes include new section relating to COVID-19 vaccines, addition of newly licensed vaccine for hepatitis B
Suicide Rates Up for Most Race, Ethnic Groups in 2018 to 2021
Highest age-adjusted 2021 suicide rates and highest relative percentage change seen for American Indian or Alaska Native persons